A potential first: COMP360 and the promise of a psilocybin medicine for severe depression

The headline landed with the particular mix of hope and caution that defines much of modern psychedelics reporting: Compass Pathways says its psilocybin candidate, COMP360, produced meaningful improvements for people with treatment‑resistant depression in two Phase 3 trials. If regulators agree, COMP360 could become the first approved psilocybin‑based medicine — and only the second psychedelic‑derived drug after Johnson & Johnson’s Spravato. That’s a big deal, but it’s also the start of another complicated conversation about efficacy, safety, access, and what “success” really means for people who have run out of options.

What matters most right now

• Compass announced two positive Phase 3 readouts showing statistically significant improvements on the MADRS depression scale at Week 6. (statnews.com)
• The trials show a rapid onset of effect (some patients reporting improvement by the day after dosing) and some durability through later follow‑up in at least one study arm. (ir.compasspathways.com)
• Compass has requested an FDA meeting and intends to pursue a rolling NDA submission, targeting completion of the filing later in the year. (ir.compasspathways.com)

A little background that frames the excitement

• Treatment‑resistant depression (TRD) generally means a patient hasn’t responded to two or more antidepressant treatments. TRD is common, debilitating, and costly — clinically and personally. Novel approaches that deliver rapid relief would be transformative.
• COMP360 is a synthetic, proprietary formulation of psilocybin administered in a controlled, therapeutic context (dosing sessions plus psychological support). Compass has been running two parallel Phase 3 trials: COMP005 (single‑dose design) and COMP006 (two doses three weeks apart). (ir.compasspathways.com)
• This program builds on prior Phase 2 work and growing evidence that classic psychedelics, paired with therapy, can produce meaningful changes in mood and cognition for some patients. But psychedelics aren’t a universal fix — and clinical trials face unique blinding and placebo challenges. (theguardian.com)

Reading the results with sensible optimism

What Compass reported is encouraging but not unequivocal. Here are the key technical points that shape how to interpret the news:

• Statistically significant but modest mean differences: The primary endpoint in the most recent trial showed a mean MADRS difference of about -3.8 points (25 mg vs 1 mg) at Week 6 — statistically significant, and described by Compass as “clinically meaningful.” Context matters: group mean differences in depression trials can underestimate benefit for individual responders, but regulators weigh both average effect and responder/remission rates. (ir.compasspathways.com)
• Rapid effects: Multiple reports emphasize a fast onset — some patients reporting improvement by the day after dosing — which is distinct from conventional antidepressants that typically take weeks. Rapid relief can be especially important in severe, suicidal, or highly incapacitating depression. (ir.compasspathways.com)
• Durability and retreatment: Compass reported durability through Week 26 for many participants in COMP005 and suggested that a second dose helped some people who had not fully remitted by six weeks. Durability of benefit without frequent repeat dosing will be crucial for adoption and payer decisions. (ir.compasspathways.com)
• Safety profile: Compass reports no unexpected safety findings and that adverse events were generally mild to moderate and transient. Still, the psychedelics space must remain alert to rare but serious psychiatric adverse events and to the challenges of scaling therapy‑intensive treatments safely. (ir.compasspathways.com)

How regulators and clinicians will look at this

• Regulators want both robust statistical evidence and clinically meaningful benefits for patients. The FDA will review full datasets, not headlines — that includes remission and responder rates, subgroup analyses, safety signals, durability, and real‑world feasibility considerations. Compass has asked for a meeting and is planning a rolling NDA submission. (ir.compasspathways.com)
• Clinicians and payers will ask: who benefits most? How durable is the effect? How many supervised sessions and trained therapists are required? What are the risks in real‑world settings? Answers to those questions will determine whether COMP360 becomes a narrowly used specialty treatment or a broadly accessible option. (statnews.com)

The access and implementation puzzle

Even if COMP360 wins approval, substantial obstacles remain before many patients benefit:

• Delivery model: Psilocybin treatment, as tested, pairs drug administration with extended therapeutic support. That requires trained facilitators, clinic space, monitoring, and billing pathways — all of which add cost and complexity.
• Workforce and training: There’s a practical shortage of clinicians trained to deliver psychedelic‑assisted therapy at scale. Building that workforce will take time, standardized curricula, and possibly new professional roles.
• Cost and coverage: Payers will weigh the drug cost plus therapy sessions against clinical benefit and alternative treatments (including Spravato and standard antidepressants). Demonstrating durable remission and reduced overall health costs will strengthen the case for coverage.
• Equity concerns: If early access remains primarily private or clinic‑based, underserved patients may be left behind, worsening disparities in mental‑health care. (washingtonpost.com)

Where COMP360 fits in the broader psychedelic landscape

• COMP360 could be the first approved classic psilocybin medicine, which would be a regulatory milestone and likely accelerate investment and research across the field. But one approval doesn’t settle debates about indications, dosing strategies, or the therapeutic model. (statnews.com)
• Other psychedelics (ketamine derivatives like Spravato, MDMA for PTSD, DMT trials) are advancing along parallel tracks. Each compound has a different pharmacology, therapeutic profile, and logistical footprint — meaning multiple psychedelic options could coexist, each suited to distinct patients and settings. (theguardian.com)

My take

This is a meaningful step. The consistency of two positive Phase 3 readouts moves COMP360 from hopeful experiment toward a plausible treatment option. The truly consequential questions now aren’t just whether regulators will approve COMP360, but who will be able to access it, how durable its benefits are in routine care, and whether health systems can deliver it safely and equitably. Hype is easy; the hard work is operationalizing evidence into care that reaches the people who need it most.

What to watch next

• The FDA meeting and the timing/details of Compass’s NDA rolling submission. (ir.compasspathways.com)
• Full trial publications or datasets showing remission and responder rates, subgroup analyses (e.g., by severity, comorbidity), and safety details beyond Week 6. (statnews.com)
• Real‑world pilots and payer decisions that will reveal how accessible and sustainable psilocybin therapy can be outside trials.

Sources

• Compass Pathways: “Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment‑Resistant Depression.”
  https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-Second-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx

• STAT: “Compass says its psilocybin drug helped patients with severe depression in two trials.” Elaine Chen, Feb. 17, 2026.
  https://www.statnews.com/2026/02/17/compass-pathways-comp360-psilocybin-severe-depression-trial-results/

• The Washington Post: Health Brief (coverage mentioning COMP360 and regulatory plans), Feb. 17, 2026.
  https://www.washingtonpost.com/wp-intelligence/health-brief/2026/02/17/americas-food-fight/

• The Guardian: coverage of psychedelic clinical research and context on risks and hype.
  https://www.theguardian.com/science/2023/aug/19/therapeutic-potential-hallucinogens-risky-overhyped-lsd-mdma-psilocybin-work

Final note: these developments are unfolding quickly. The next weeks — regulatory meetings, full data disclosures, and peer‑reviewed publications — will be the best place to revisit whether COMP360’s promise holds up in the detailed numbers and in real‑world practice.

When a Memo Becomes a Firestorm: What the Former FDA Chiefs Are Really Saying About Vaccine Policy

The moment an internal memo from a high-ranking FDA official leaked and landed in public view, it felt less like an agency debate and more like a political grenade. The memo — authored by Vinay Prasad, the FDA’s chief medical and scientific officer overseeing vaccines — alleged that COVID-19 vaccines had likely contributed to the deaths of at least 10 children and proposed sweeping changes to how vaccines are evaluated and updated. The reaction was immediate: a bipartisan group of 12 former FDA commissioners publicly pushed back, calling the memo and the proposed policy shifts a serious misstep that “misrepresent[s] both the science and the regulatory record.” (arstechnica.com)

Why this matters beyond headlines: vaccine regulation isn’t just arcane bureaucracy. It determines how quickly improved vaccines reach people, how safe products are vetted, and — crucially — whether public trust in vaccines withstands political winds. The battle unfolding is about science, process, and the credibility of institutions Americans rely on for public health.

Why the former commissioners pushed back

• They say the memo used selective and poorly explained evidence — notably raw VAERS reports — to make startling causal claims about child deaths without transparent analysis. VAERS is a crowdsourced surveillance tool designed to flag signals, not prove causation; experts routinely review those reports and follow up with clinical investigation. The commissioners noted that FDA staff had previously reviewed many of the same reports and reached different conclusions. (arstechnica.com)

• They argue the proposed regulatory overhaul would replace long-accepted tools (like immunobridging — using immune response data to infer effectiveness for vaccine updates) with demands for randomized trials for every update. That could slow vaccine updates, inflate costs, reduce competition, and make rapid responses to evolving viruses — e.g., seasonal flu or new variants — far harder. (arstechnica.com)

• They worry process and transparency are being sidelined. Big changes to regulatory frameworks usually go through public rulemaking, advisory panels, and open scientific debate. The commissioners said the memo offered “no explanation of the process and analyses” underpinning its judgments and cautioned against unilateral shifts that bypass oversight. (reuters.com)

What Prasad proposed (in plain language)

• Reassess the use of immunobridging studies — meaning, instead of approving updates based on lab-measured immune responses, require larger randomized clinical trials to show direct clinical benefit.
• Revisit the FDA’s approach to annual vaccines like flu shots and to simultaneous administration of multiple vaccines.
• Highlighted alleged adverse-event signals (the 10 child deaths) as a rationale for the policy change. (arstechnica.com)

These are not trivial technical adjustments. They amount to a new philosophical stance about what counts as adequate evidence — and they would reshape the economics and pace of vaccine development.

How scientists and former regulators see the risk

• Slower updates for evolving viruses: Immunobridging is widely used precisely because it lets manufacturers swap antigens or tweak a formulation quickly while relying on established correlates of protection. For fast-moving pathogens, speed can save lives. (statnews.com)

• Higher barriers = fewer players: Randomized trials for incremental updates are expensive. Smaller manufacturers and new entrants could be squeezed out, concentrating the market and potentially raising prices.

• Erosion of trust: Dramatic claims based on surveillance signals, without transparent methods, risk amplifying vaccine skepticism — especially if the public perceives the FDA as politicized or inconsistent. The former commissioners explicitly frame open deliberation and visible procedures as the cure for shaken confidence. (arstechnica.com)

The politics beneath the science

This row isn’t happening in a vacuum. The memo arrived amid leadership changes at HHS and an administration that includes officials publicly skeptical of vaccines. The hiring of Prasad by Health Secretary Robert F. Kennedy Jr. — a figure long associated with vaccine criticism — has sharpened the optics. That doesn’t invalidate scientific critique, but it does mean scientific decisions will be filtered through a politically charged environment, which makes transparency and method even more important. (washingtonpost.com)

A few short, practical takeaways

• Rapid vaccine updates rely on a balance of evidence types; immunobridging has been a practical, evidence-based compromise. Replacing it with blanket randomized-trial requirements would be costly and slow. (statnews.com)

• VAERS is a signal-detection system, not proof of causation. Claims that depend on raw VAERS counts without clinical adjudication are scientifically weak and risk misinforming the public.

• Institutional legitimacy depends as much on process as it does on outcome. Major scientific-policy shifts need public, peer-reviewed reasoning, not unilateral memos. (reuters.com)

My take

Policy change is healthy when it’s evidence-based, transparent, and debated openly. The former FDA chiefs’ intervention reads like a call to restore those norms: don’t rewrite the rulebook on the basis of opaque analyses and surveillance signals. If there are real problems in how vaccine safety is assessed, identify them publicly, lay out the methods and data, and let the scientific community and independent reviewers weigh in. That’s how trust is rebuilt — not by dramatic internal proclamations that read like verdicts before the evidence is shown.

Final thoughts

This episode is a reminder that public-health institutions live by two currencies: scientific rigor and public trust. You can’t transact in one without protecting the other. Whether the memo sparks constructive reform or lurches into politicized disruption will depend on whether the agency re-centers transparent methods, external review, and clear communication. For now, the chorus of former leaders is asking for a pause — and a return to the practices that made the FDA a global gold standard in the first place. (arstechnica.com)

Sources

• 12 former FDA chiefs unite to say agency memo on vaccines is deeply stupid — Ars Technica.
  https://arstechnica.com/health/2025/12/12-former-fda-chiefs-unite-to-say-agency-memo-on-vaccines-is-deeply-stupid/ (arstechnica.com)

• Twelve former US FDA commissioners express deep concern about agency's vaccine change — Reuters.
  https://www.reuters.com/business/healthcare-pharmaceuticals/twelve-former-us-fda-commissioners-deeply-concerned-about-agencys-vaccine-change-2025-12-03/ (reuters.com)

• A dozen former FDA commissioners decry Prasad memo on vaccine regulation — STAT.
  https://www.statnews.com/2025/12/03/fda-former-commissioners-vaccine-policy/ (statnews.com)

• Unpacking the FDA’s Black Friday Vaccine Memo — FactCheck.org.
  https://www.factcheck.org/2025/12/unpacking-the-fdas-black-friday-vaccine-memo/ (factcheck.org)

• Former FDA commissioners condemn plan to tighten vaccine approvals — The Washington Post.
  https://www.washingtonpost.com/health/2025/12/03/fda-commissioner-letter-vaccine-approval/ (washingtonpost.com)